Have a feature idea you'd love to see implemented?
Let us know!
XENE Xenon Pharmaceuticals Inc
Price (delayed)
$39.42
Market cap
$2.99B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.74
Enterprise value
$2.86B
Xenon is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. The Company is advancing a novel product pipeline of
Highlights
XENE's debt is down by 13% year-on-year and by 3.8% since the previous quarter
The company's equity rose by 31% YoY but it fell by 4.9% QoQ
The quick ratio has contracted by 27% from the previous quarter but it has grown by 20% YoY
The company's revenue has shrunk by 100% YoY
Xenon Pharmaceuticals's gross profit has plunged by 100% YoY
Key stats
What are the main financial stats of XENE
Market
Valuations
Earnings
Shares outstanding
75.76M
Market cap
$2.99B
Enterprise value
$2.86B
Price to earnings (P/E)
N/A
Price to book (P/B)
3.52
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$199.34M
EBITDA
-$195.5M
Free cash flow
-$156.53M
Per share
Balance sheet
Liquidity
EPS
-$2.74
Free cash flow per share
-$2.02
Book value per share
$11.18
Revenue per share
$0
TBVPS
$11.38
Total assets
$884.01M
Total liabilities
$39.96M
Debt
$10.03M
Equity
$844.05M
Working capital
$696.8M
Debt to equity
0.01
Current ratio
23.27
Quick ratio
23.09
Net debt/EBITDA
0.65
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-23.2%
Return on equity
-24.2%
Return on invested capital
-27.2%
Return on capital employed
-23.4%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
XENE stock price
How has the Xenon Pharmaceuticals stock price performed over time
Intraday
-3.9%
1 week
-3.48%
1 month
2.1%
1 year
11.07%
YTD
-14.42%
QTD
0.13%
Financial performance
How have Xenon Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$237.52M
Net income
-$199.06M
Gross margin
N/A
Net margin
N/A
The company's revenue has shrunk by 100% YoY
Xenon Pharmaceuticals's gross profit has plunged by 100% YoY
The operating income is down by 28% year-on-year and by 6% since the previous quarter
The net income has declined by 22% year-on-year and by 6% since the previous quarter
Growth
What is Xenon Pharmaceuticals's growth rate over time
Valuation
What is Xenon Pharmaceuticals stock price valuation
P/E
N/A
P/B
3.52
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS fell by 10% YoY
The company's equity rose by 31% YoY but it fell by 4.9% QoQ
XENE's price to book (P/B) is 22% higher than its 5-year quarterly average of 3.0 and 4.9% higher than its last 4 quarters average of 3.5
The company's revenue has shrunk by 100% YoY
Efficiency
How efficient is Xenon Pharmaceuticals business performance
XENE's return on invested capital is down by 8% year-on-year
Xenon Pharmaceuticals's return on equity has decreased by 3.9% YoY
Xenon Pharmaceuticals's return on assets has decreased by 4% YoY
Dividends
What is XENE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for XENE.
Financial health
How did Xenon Pharmaceuticals financials performed over time
The total assets rose by 29% year-on-year but it has declined by 3.8% since the previous quarter
XENE's total liabilities is up by 28% since the previous quarter and by 4% year-on-year
XENE's debt is 99% smaller than its equity
The company's debt to equity has shrunk by 50% YoY
The company's equity rose by 31% YoY but it fell by 4.9% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.